STOCK TITAN
  1. Home
  2. Sec-filings
  3. KURA
  4. [Form 4] Kura Oncology, Inc. Insider Trading Activity

Kura Oncology (KURA) CCO sells 339 shares while retaining 183,614

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported an open-market sale of 339 shares of common stock at $9.21 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following this sale, he directly holds 183,614 shares of Kura Oncology common stock.

Positive

  • None.

Negative

  • None.
Insider Powl Brian T.
Role Chief Commercial Officer
Sold 339 shs ($3K)
Type Security Shares Price Value
Sale Common Stock 339 $9.21 $3K
Holdings After Transaction: Common Stock — 183,614 shares (Direct, null)
Footnotes (1)
  1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025. 678 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
Shares sold 339 shares Open-market sale of common stock on May 19, 2026
Sale price $9.21 per share Price for the 339-share open-market transaction
Shares held after sale 183,614 shares Direct holdings of Brian T. Powl following the transaction
ESPP acquisition 678 shares Acquired on May 17, 2026 via Employee Stock Purchase Plan
10b5-1 plan adoption date December 18, 2025 Date Powl adopted the Rule 10b5-1 trading plan
Rule 10b5-1 trading plan regulatory
"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"678 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
beneficial ownership financial
"Form 4 provides transparency into changes in his beneficial ownership of company common stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Powl Brian T.
(Last)(First)(Middle)
C/O KURA ONCOLOGY, INC.
4930 DIRECTORS PLACE, SUITE 500
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/19/2026S(1)339(2)D$9.21183,614D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.
2. 678 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
Teresa Bair, Attorney-in-fact for Brian Powl05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kura Oncology (KURA) report for Brian T. Powl?

Brian T. Powl reported selling 339 shares of Kura Oncology common stock. The shares were sold in an open-market transaction at $9.21 per share, reflecting a small disposition relative to his remaining direct holdings.

What is Brian T. Powl’s role at Kura Oncology (KURA)?

Brian T. Powl serves as Chief Commercial Officer of Kura Oncology. His position as a senior executive makes his equity transactions reportable on Form 4, providing transparency into changes in his beneficial ownership of company common stock.

How many Kura Oncology (KURA) shares does Brian T. Powl hold after this sale?

After the reported sale, Brian T. Powl directly holds 183,614 shares. This figure reflects his remaining beneficial ownership of Kura Oncology common stock as disclosed in the Form 4 following the 339-share open-market transaction.

Was the Kura Oncology (KURA) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan. The plan was adopted by Brian T. Powl on December 18, 2025, indicating the transaction timing was pre-arranged rather than discretionary.

Did Brian T. Powl recently acquire Kura Oncology (KURA) shares through an employee plan?

Yes. A footnote notes he acquired 678 shares on May 17, 2026. These shares were obtained through Kura Oncology’s Employee Stock Purchase Plan, adding to his equity position separate from the small open-market sale disclosed.

What does a Form 4 filing for Kura Oncology (KURA) indicate to investors?

Form 4 filings show changes in insider ownership of Kura Oncology stock. They disclose when executives or other insiders buy, sell, or otherwise change their holdings, helping investors track management’s equity positions over time.